{"name":"Edgewise Therapeutics","slug":"edgewise","ticker":"EWTX","exchange":"NASDAQ","domain":"edgewisetx.com","description":"Edgewise Therapeutics is a biopharmaceutical company focused on developing innovative treatments for rare and orphan diseases, with a primary focus on cardiology and muscle biology. The company's lead product, EDG-5506, is being developed for the treatment of Duchenne muscular dystrophy. Edgewise Therapeutics is a relatively small company with a limited product portfolio, but its pipeline holds promise for addressing significant unmet medical needs.","hq":"Boulder, CO","founded":0,"employees":"","ceo":"Kevin Koch","sector":"Cardiology / Rare Disease / Muscle Biology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.2B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":151389000,"netIncome":-167795000,"cash":552603000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Edgewise Therapeutics Announces FDA Clearance of IND for EDG-5506","summary":"Edgewise Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for EDG-5506, enabling the company to initiate a Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy.","drugName":"EDG-5506","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Edgewise Therapeutics Reports Third Quarter 2022 Financial Results","summary":"Edgewise Therapeutics reported its financial results for the third quarter of 2022, highlighting a net loss of $13.4 million and a cash balance of $123.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"trial","source":"simplywall.st","summary":"Why Edgewise Therapeutics (EWTX) Is Up 8.1% After New Sevasemten BMD Data And Analyst Interest - simplywall.st","headline":"Why Edgewise Therapeutics (EWTX) Is Up 8.1% After New Sevasemten BMD Data And Analyst Interest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQT21UZHl6aUN4ZHVnbHdTckRSc3JyRy1JdWhSWHFtQUtzYkNXM1RlYXhGd3hIam9lbDBPeDhzY0o3SU5ycnBGbkh4blN6bmVKOHl2Wk1IUW5sRFNaZnhwNVZsUWNyOXVYUElNRmpIQ1A0SEhEOFdpVWc0ZnlxZ1RFNy1KNl9iMFdBMnoybHhwRTZQWjFiZTRsLW4xeGZkVzhRcUFQcGdHRkxNcjhxaHRUTTJyQmxVNVJIb1pCSld2Rk96bF9MSWM5Mkkxb2dvMXNvWFNlZlBzamJWeVd0?oc=5","date":"2026-04-05","type":"trial","source":"Sahm","summary":"Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data - Sahm","headline":"Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNNF9zSlJKNE55QlRLbk1YLTdJcFNkYlRnYTVPaE5GTVVMYVU3X0cyelpwaHdEV0dqQnBUc2twaHJPbV9ITFUzWFdBWm54Ri02UGJOOWl0MlFKbjN1ZWZqWEd2UUgza0g4UUUwTFd4Z2hHSnRKcGN6OV84MXVVUURKOS1uRUpidzZ5ZFRGNnNDNUQ0bk9fclMzTEY3SjRUcUdHNk9SajF3TWd3MnhEbEhjVjRyV3pESWVpbkl3NVJBMm5MRFByNVNldnRycmZyY0VBa0gtMTRFQTNuRFVRN3gxZG9SZndDR3IxMEZr0gHwAUFVX3lxTE9zeUlCdEFwZml5VVNncnpkNWZkby1TaElSQno5Xy1aUllNbzVqc2dXWU5iVVl1dzFfT1NtcnFCOVl1R3YweWR1dUdFYTlxcjVRemJDckdlYzNHWUs4cXVlQzRiYjF4VWpJdG1Kb1FIUzA3LWo3aTdrTmtLN0hxV01XZWRaT2Z4Uks2TGE0Z05yVWdFRkcteWdIejgtN2lNQTBDa2lfWk9zRF80QVFUYmhfdXU5M2ZjRFo3ZGRLUzFNZE9GLURIbDZWUDYxNHlzZ2NpSHdoUjVKakRkU0JOOHo1QXM1Rk5DZndyWi1wQW9iYQ?oc=5","date":"2026-04-04","type":"trial","source":"simplywall.st","summary":"Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data - simplywall.st","headline":"Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPSkhVTWxER0dmYXpQNVpWYkd0M3UtVnIyOXlpOGlmai1ELTh6U2xFVDAwNzFWUlRFWGE4Zy1sYXA3SjBLcVpqRTlnTy1qLTJyTlZwSktoVy1NVDFRdTJxb2RLQXBXMFA2aDlGT2VkS3VLeWd0dk9iZUtfYnFjVW1WUGhXdFhaWGJMSktQZ3FuSUc1allnRVRV?oc=5","date":"2026-03-16","type":"trial","source":"Yahoo Finance","summary":"Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results - Yahoo Finance","headline":"Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-15","type":"trial","source":"simplywall.st","summary":"Edgewise Therapeutics (EWTX) Is Up 6.4% After New Long-Term Becker Data On Sevasemten Trial - simplywall.st","headline":"Edgewise Therapeutics (EWTX) Is Up 6.4% After New Long-Term Becker Data On Sevasemten Trial","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPMXI4a2NNM2FPM183OU4wMjR5azhzNW1xM0VKRFpUMkdEQWJMVG5uUG1Cb3VyZEVTbWtfWDlTQy1sUjNHTmdSRE9vY2VpbXczdFZoVWFwcnNySHRfRkhhcXlKZzZvQkt0V3djV3hsUTA2ZFoyUTNrOUNZdDRIZ2tIMzE5bEExVGx0Uk9Cd1VRS1h3a0wwblhhZDhxUmVIQ2JVVFJGQzVxWlRvT3JieEVaMFY2TTMxVFg2al9RcTRPNHJNUkhRcVM1ZmFsR1hiTEIyTDM0ZDB3?oc=5","date":"2026-01-13","type":"pipeline","source":"PR Newswire","summary":"Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - PR Newswire","headline":"Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPdlNJNjlFVUFWNHZtUnZUa1ZSZ0dibWVFZE5RWElpMVJlVmt3Mzk3TjY1QVVQMm1VZ3pUR2dVZ0FRVzZ5Mi1KMEczdk5LbzdtWjZ5MWdJMkU4WkFHeDRpWk5SV2gtcmtQb2E2OHpPX3czWW9iVnNSdUcyclp1T2x0Rm1JMUFxaWlSSEtILXZYbzF4a094MHhFc2phYi0wOXZZX2haWlhhMlhpVFFkMjQwUUJqNEpDQQ?oc=5","date":"2025-12-29","type":"trial","source":"Seeking Alpha","summary":"Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX) - Seeking Alpha","headline":"Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQd2JXdnFXT3M1QVhxek04OXhtenBMQl9jYlNFMGxtMXJZdjdBOXd3MFhxdzR0NW04NVNRRUdTaGY4T3piZ2xDWWcyaDdXbDU0Q1NUaEtLcU9taDZOQXBhakpVQ0hFSU56SkxRWlZFOFlack16X3lVZGxFdi1jRS1JNll5TnpRSDMtVzF3VzZxeDhsaXF0T3MxMTBQQldOY0ZHX2NHSmNTVmZnOXVDd19SX2tmMGdYU3IzSTY2c3NIYmNidm1QZWFXUG53MTFMSlNZemc?oc=5","date":"2025-12-26","type":"pipeline","source":"TechStock²","summary":"Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas - TechStock²","headline":"Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNWWtMVzVya19hMHlXMThtcDRpUVRmYzFsQmNlb3VRNW1Jc3JBMUVWVUp6UVVLazYyMnNZTHR0TzdjUWVTcktSRjhncDJtdEQ2Sjc0Tzc3UGZpRDJ5bmpxOGp6N3hKa3psYjllSzUyYUMzSWx0ZnI1N0s0ZEZQWVFtV25yOWt5TGZORTB1TWFhTGEtczAySFJfaGg2Y1RRc3k2Ykd3TzVRRV9UNEVJS18zWnFpXzhLYUJsc2tvbElQaWVwd0hGSWxZcWRheC1XY1YzM0VuWmlzcWlVZw?oc=5","date":"2025-12-24","type":"pipeline","source":"TechStock²","summary":"Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts - TechStock²","headline":"Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNc3FxekVBdXlsTUU0aVV1cDhxMHBjd1lmOERFTG8tSnExOXJJTHdHaVZDbVRZME5yV1h2U2taZ1lmX1Q3Z1lwamRtMU41U3pkX2R2elZsblVWNXZJYlJYb0ZqSlJBZFV4c1o2Qk1raHVRWTdwckp2MXEtMjNsWGgtV082bFJJVEhFYWctNVNGZEZIYkc3NFYwSDRLc2t0RU9xMFNtUnVLZjB6aEpib3lRdS0tSGRPUHB1OUpYeVN2V05oR2M?oc=5","date":"2025-12-20","type":"pipeline","source":"TechStock²","summary":"Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - TechStock²","headline":"Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - TechSto","sentiment":"neutral"},{"date":"2025-11-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNd2VUSE94RExNY0ZKdjc2T3I1dHFBMlo5cmpkdkJXampmX0p4akJoNjNvZ1FzeC1xSnA5S3ZFOUhmNUx2STkwQTlhVzdmci1ZSmZWdmMyQlFvaEtKNDg0RXEzOHJWbGo2R1FmUkhpRXVqSncwbHhxZlZjMWVhcFpYWWMtNm90Q0ZJalZQeEVMMmY4ck9pMGNZZjczSEVGdE92dW1pZ3U5bnA4cnFrcHBjX0FjU1JSWFVOc2VET2JEODNRUGlNbm9HV2VoME04MTFQVTB2MUdpcXVYMFB5WTZ0b2dxMUdqLS0zUmc?oc=5","date":"2025-08-07","type":"earnings","source":"PR Newswire","summary":"Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire","headline":"Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPZGNJeVdzOUZST1k0c0dtVXJBb3ZIeU9FWFoyczB2LUgwcE5BX24yT0stZ0R2c0hmMFFRVnZmMEttVm5DdkdFSVpuaUhVdDF5VzlfYzJ5RUo2WnRpZUFwR0xXUTlCMUZRMGdmOTdTSTBISF9SR2NNVUZ6dHRQWVF2UE9hRFU4SUF6Wnh1VnIxaElTbzY5QVk1Sm53Y3lIRDZyaUgxcGVn?oc=5","date":"2025-04-02","type":"trial","source":"Investopedia","summary":"Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia","headline":"Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'","sentiment":"negative"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Biogen","Sarepta Therapeutics"],"therapeuticFocus":["Cardiology","Rare Disease","Muscle Biology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":151389000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-167795000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":552603000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}